FindTrial
Sign In

Axalimogene filolisbac

BIOLOGICAL2 trials

Sponsors

Advaxis, Inc.

Conditions

Anal CancerCervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell CarcinomaEffects of ImmunotherapyMetastatic/Recurrent Cervical CancerRectal Cancer

Phase 1

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
CompletedNCT02164461
Advaxis, Inc.Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma +6
Start: 2015-03-04End: 2017-03-08Updated: 2024-05-20

Phase 2

A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
CompletedNCT02399813
Advaxis, Inc.Anal Cancer, Rectal Cancer
Start: 2016-06-02End: 2019-01-03Updated: 2023-03-20

Related Papers

Phase I study evaluating high-dose treatment with ADXS11-001, a <i>Listeria monocytogenes</i>-listeriolysin O (<i>Lm</i>-LLO) immunotherapy, in women with cervical cancer.
Journal of Clinical Oncology2016-05-207 citations
Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal.
Journal of Clinical Oncology2016-02-015 citations
Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix.
Journal of Clinical Oncology2015-05-203 citations